Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediGene progresses on two fronts

This article was originally published in Scrip

Executive Summary

MediGene has seen a modest uptick in its share price after announcing progress with two of its products. The company's share stood at €1.09 in mid-afternoon trading on the Frankfurt stock exchange on 12 December (up from €1.06 on 9 December and €1.02 on 8 December) after announcing that its genital wart ointment Veregen had been accepted for review in 17 European countries. The product, which was previously known as Polyphenon E and is derived from green tea leaves, is already available in the US, Germany and Austria, and has been granted approval in Spain, with launch there expected next year.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015531

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel